Celiac disease products


Celiac disease affects 1% of the population and therefore is the most common chronic inflammation of the small intestine triggered by cereal gluten/gliadin uptake in genetically susceptible individuals. The gluten induced autoimmune disorder is characterized by autoantibodies to tissue transglutaminase (TG2), antibodies to deamidated gliadin and villous atrophy in the final stage.

TG2 plays a central role in celiac disease. Besides being the major autoantigen it is involved in the pathogenesis. Under certain circumstances and in distinct environments as given in the inflamed gut TG2 catalyzes deamidation of glutamine side chains in gliadin yielding glutamic acid. Deamidated gliadin is subsequently recognized by receptors of the immune system triggering celiac disease.

Related gluten induced autoimmune disorders are dermatitis herpetiformis / Morbus Duhring (autoantigen: epidermal transglutaminase, TG3).


Gluten-sensitive neurological disorders like Gluten ataxia may be accompanied by auto- antibodies to neuronal transglutaminase (TG6). Its detection is part of the “Guidelines on the diagnosis and management of the progressive ataxias” (de Silva et al., 2019).
Detection of TG6-autoantibodies in human sera is possible using our ELISA-Kits E103 (anti-TG6-IgA) and E104 (anti-TG6-IgG).

Analytical service for measurement of TG6-autoantibodies in human serum samples

In co-operation with the medical laboratory of Prof. Dr. med. M. Kramer (board-certified clinical pathologist) in Heidelberg, Germany we provide testing services for the determination of Transglutaminase auto-antibodies in patient serum samples.

Order Sheet (English).pdf
Bestellformular (Deutsch).pdf

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events  

  • Canceled: Gordon Research Conference - Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy